全身血栓烷生成与心力衰竭发病风险的相关性
在2611例无心力衰竭史且左室射血分数≥55%的Framingham心脏研究参与者中,尿血栓烷B2代谢物经肾小球滤过率校正后(TXB2-MGFR)与中位14.8年随访期间新发心力衰竭风险独立相关(HR 1.81,95%CI 1.38-2.64,P<0.0001),且两种心力衰竭亚型均显示关联。
要点
- 尿TXB2-MGFR升高与心力衰竭发病风险增加独立相关。
- 该关联在射血分数保留和降低的心力衰竭亚型中均存在。
- 阿司匹林使用或血小板活化指标与心力衰竭风险无独立关联。
核心结论
- 全身血栓烷A2生成以尿TXB2-MGFR评估,与心力衰竭发病风险显著相关,校正传统危险因素后仍存在。
研究设计与样本
- 研究纳入2611例Framingham心脏研究参与者(54.9%女性,平均年龄65±9岁,43.8%使用阿司匹林),均无心力衰竭史且左室射血分数≥55%。
- 尿TXB2-M经免疫测定并校正尿浓度和肾功能(TXB2-MGFR),采用Cox回归分析中位14.8年随访期间的心力衰竭风险。
主要发现
- 随访期间189例(7.2%)发生心力衰竭,其中104例(55.0%)为射血分数保留的心力衰竭,56例(29.6%)为射血分数降低的心力衰竭,29例(15.3%)无法分类。
- 阿司匹林使用者TXB2-MGFR高于16.6 filtered prostanoid units、非使用者高于62.1 filtered prostanoid units时,心力衰竭风险增加(HR 1.81;95%CI 1.38-2.64;P<0.0001)。
- 射血分数保留的心力衰竭HR 1.81(95%CI 1.17-2.80;P=0.0081),射血分数降低的心力衰竭HR 2.63(95%CI 1.48-4.68;P=0.0010)。
- 阿司匹林使用或血浆P-选择素评估的血小板活化均与心力衰竭风险无独立关联。
临床怎么用
- 尿TXB2-MGFR可作为潜在新型生物标志物,识别可能从积极一级预防中获益的心力衰竭高危个体。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Systemic thromboxane A2 generation, which is readily assessed by quantifying thromboxane B2 metabolites (TXB2-M) in the urine, is associated with impaired cardiac performance and mortality in aspirin (ASA) users with heart failure (HF). OBJECTIVES: This study sought to determine the association of urinary TXB2-M with the risk of developing HF in individuals without prior history of HF and with normal left ventricular function irrespective of ASA use. METHODS: Urine TXB2-M were measured by immunoassay and adjusted to urine concentration and renal function (TXB2-MGFR) in 2,611 Framingham Heart Study participants (54.9% women, mean age 65 ± 9 years, 43.8% ASA users) without prior history of HF and with left ventricular ejection fraction (LVEF) ≥55%. The association of TXB2-MGFR with HF risk over a median observation period of 14.8 years (Q1-Q3: 12.6-15.7 years) was modeled using Cox regression. RESULTS: HF occurred in 189 participants (7.2%), with 104 of the first events (55.0%) classified as HF with preserved LVEF, 56 (29.6%) as HF with reduced LVEF, and 29 (15.3%) were unclassifiable. TXB2-MGFR levels, above compared to below, of 16.6 and 62.1 filtered prostanoid units for ASA users and nonusers, respectively, were associated with increased risk of developing HF (HR: 1.81; 95% CI: 1.38-2.64; P < 0.0001, adjusted for age, sex, ASA use, and HF risk factors), including both HF subtypes (HF with preserved LVEF: HR: 1.81; 95% CI: 1.17-2.80; P = 0.0081, and HF with reduced LVEF: HR: 2.63; 95% CI: 1.48-4.68; P = 0.0010, adjusted for age, sex, ASA use, and cardiovascular disease). Neither ASA use nor evidence of platelet activation, as measured by plasma P-selectin, were independently associated with HF risk. CONCLUSIONS: Systemic thromboxane A2 generation as measured by urinary TXB2-MGFR was significantly associated with HF risk and remained so after accounting for traditional risk factors. Urinary TXB2-MGFR is therefore a potentially useful novel biomarker to identify at-risk individuals who might benefit from aggressive primary prevention.
引用
- Rade, Kronsberg, Kickler, et al. Association of Systemic Thromboxane Generation With Risk of Developing Heart Failure. J Am Coll Cardiol. 2025. PMID: 39779056. doi:10.1016/j.jacc.2024.09.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。